Correspondence 0001193125-23-229644 from ImageneBio, Inc. (IMA)
ImageneBio, Inc.
Date: Sept. 6, 2023 · CIK: 0001835579 · Accession: 0001193125-23-229644
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-274072
Letter
Re: Ikena Oncology, Inc.
September 6, 2023
Via EDGAR Transmission
United States Securities and Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, D.C. 20549
Acceleration Request for Registration Statement on Form S-3
File No. 333-274072
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Ikena Oncology, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to September 8, 2023, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
If you have any questions regarding this request, please contact Stephanie Richards of Goodwin Procter LLP at (617) 570-1927.
Sincerely,
IKENA ONCOLOGY, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP September 6, 2023 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Ikena Oncology, Inc. Acceleration Request for Registration Statement on Form S-3 File No. 333-274072 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Ikena Oncology, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to September 8, 2023, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. If you have any questions regarding this request, please contact Stephanie Richards of Goodwin Procter LLP at (617) 570-1927. Sincerely, IKENA ONCOLOGY, INC. /s/ Mark Manfredi, Ph.D. Mark Manfredi, Ph.D. Chief Executive Officer cc: Mark Manfredi, Ph.D., Chief Executive Officer, Ikena Oncology, Inc. Stephanie Richards., Esq., Goodwin Procter LLP